DDD stages

IND

Orexo announces positive outcome from in vivo study of OX390

Orexo AB has announced positive data from a pre-clinical in vivo study on the nasal absorption of atipamezole when delivered with Orexo’s AmorphOX® drug delivery technology. The study...
Read more
IND

MEKanistic Therapeutics announces FDA clearance of IND for MTX-531, enabling phase 1 trials in advanced solid tumours

MEKanistic Therapeutics, a biotechnology company developing first-in-class precision medicines designed to overcome cancer resistance mechanisms, has announced that the US Food and Drug Administration...
Read more
IND

Matter Bio files first IND for Lm-LLO-TT, advancing first-in-human phase 1/2a study in patients with pancreatic cancer

Matter Bio has submitted its first Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) for Lm-LLO-TT, the company’s lead therapeutic candidate,...
Read more
Phase 1-2 trials

Myosin Therapeutics initiates phase 1/2 trial of MT-125 targeting non-muscle myosin II in newly diagnosed glioblastoma

Myosin Therapeutics, a clinical stage biotechnology company developing innovative therapies for oncology, has announced that the first patient has been dosed in its phase...
Read more
Drug Discovery

New clinical study shows pasteurised Akkermansia muciniphila MucT supports weight loss maintenance

The Akkermansia company has announced the publication of a new randomised, placebo-controlled clinical trial in Nature Medicine demonstrating that supplementation with pasteurised Akkermansia muciniphila MucT®, the proprietary bacterial strain...
Read more
Phase 1-2 trials

Remepy reports strong clinical phase 2a results for Hybridopa, a first-in-class hybrid drug for Parkinson’s disease

Remepy, a pioneer in hybrid drugs, has announced that the phase 2a clinical trial of Hybridopa, a new hybrid drug for Parkinson’s disease, met...
Read more
Phase 3 trials

BioMarin announces positive phase 3 pivotal study results for Voxzogo (vosoritide) in children with hypochondroplasia

BioMarin Pharmaceutical has announced that a phase 3 study evaluating treatment with Voxzogo® (vosoritide) in children with hypochondroplasia met its primary endpoint, demonstrating a statistically...
Read more
Drug Discovery

Atossa Therapeutics announces acceptance of manuscript highlighting utrophin-modulation potential of (Z)-Endoxifen in Duchenne Muscular Dystrophy

Atossa Therapeutics, a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of significant unmet clinical need, has announced that a manuscript...
Read more
- Advertisement -
Pharmconex ad
- Advertisement -
NLS Days ad
- Advertisement -
ILMAC ad
- Advertisement -
BIO Europe
- Advertisement -WVC EU

Latest posts

Load more

Drug Discovery & Development (DDD) is dedicated to advancing scientific innovations into active medical solutions. Its aim is to accelerate breakthroughs in medicine, addressing human disease and improving global health outcomes.

Menu

© Web design by Social Media Services 2026. All rights reserved.